When should we start thromboprophylaxis? The stroke risk threshold discrepancy between European and U.S. guidelines for atrial fibrillation

Back

ESC Premium Access

When should we start thromboprophylaxis? The stroke risk threshold discrepancy between European and U.S. guidelines for atrial fibrillation

Session: New trends in antithrombotic therapy for atrial fibrillation

Topic: Atrial fibrillation (AF)

Speaker: Mr P. Nielsen (Aalborg, DK)

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Mr Peter Bronnum Nielsen

Aalborg University Hospital, Aalborg (Denmark)

4 presentations

0 follower

8 more presentations in this session

Real world persistence, adherence and switch-over across anticoagulants in atrial fibrillation-a national population-based study.

Speaker: Doctor A. Banerjee (London, GB)

Patients with atrial fibrillation and history of falls are at high risk for bleeding but have less bleeding with apixaban than warfarin: results from the ARISTOTLE trial

Speaker: Doctor M. Rao (Durham, US)

Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and active cancer: insights from the ARISTOTLE trial

Speaker: Assistant Professor C. Melloni (Durham, US)

Linking intrinsic factor X activity, a biologically relevant pharmacodynamic marker, to edoxaban plasma concentration and clinical outcomes in the ENGAGE AF-TIMI 48 trial

Speaker: Doctor O. Yin (Edison, New Jersey, US)

Direct oral anticoagulants in atrial fibrillation patients undergoing cardioversion. Nationwide multicentre study.

Speaker: Miss S. Itainen-Stromberg (Helsinki, FI)

Access the full session

New trends in antithrombotic therapy for atrial fibrillation

Speakers: Mr P. Nielsen, Doctor A. Banerjee, Doctor M. Rao, Assistant Professor C. Melloni, Doctor O. Yin...

Access

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources